A Comparison of brand-name and generic versions of the anticoagulant, nafamostat mesilate, for hemodialysis

DOI Web Site 2 Citations 13 References Open Access
  • Hirashima Chika
    Division of Kidney and Dialysis, Department of Internal Medicine, Hyogo College of Medicine
  • Izumi Masaaki
    Division of Kidney and Dialysis, Department of Internal Medicine, Hyogo College of Medicine
  • Misumi Fumiko
    Department of Nursing, The Hospital of Hyogo College of Medicine
  • Kawagoe Eiko
    Department of Nursing, The Hospital of Hyogo College of Medicine
  • Suemitsu Koutaro
    Division of Kidney and Dialysis, Department of Internal Medicine, Hyogo College of Medicine
  • Nariyama Shinichi
    Division of Kidney and Dialysis, Department of Internal Medicine, Hyogo College of Medicine
  • Fukumoto Hiromi
    Division of Kidney and Dialysis, Department of Internal Medicine, Hyogo College of Medicine
  • Kiyobayashi Yuri
    Division of Kidney and Dialysis, Department of Internal Medicine, Hyogo College of Medicine
  • Nakanishi Takeshi
    Division of Kidney and Dialysis, Department of Internal Medicine, Hyogo College of Medicine

Bibliographic Information

Other Title
  • 血液透析施行時におけるメシル酸ナファモスタットの先発品と後発品の比較検討
  • ケツエキ トウセキ シコウジ ニ オケル メシルサン ナファモスタット ノ センパツヒン ト コウハツヒン ノ ヒカク ケントウ

Search this article

Description

Nafamostat mesilate has been widely used as an anticoagulant in hemodialysis patients with hemorrhagic diathesis. We compared brand-name and generic versions of the anticoagulant, nafamostat mesilate, with regard to the quantity of precipitate and the effect as an anticoagulant in twelve patients. By the cross-over method, there was no significant difference in the effects as an anticoagulant between the two versions of the drug. However, the quantity of precipitate was larger for the generic version than for the brand-name drug. The difference in the quantity of precipitate might be due to differences in additives or the level of impurities. When introducing the generic medicines, it must be considered that these versions might not be completely identical to the brand-name drug.

Journal

Citations (2)*help

See more

References(13)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top